INN breaks down everything you need to know about Australia cannabis investing and how you can enter this emerging market down under.

Since the legalisation of medical cannabis in 2016, Australia has been steadily developing its marijuana industry — and it's been attracting attention from international players and investors.

With a quickly growing population of over 25 million people and a robust agricultural industry, the country is positioned to mould itself into a major force in the international cannabis space.

Here the Investing News Network takes a look at how the cannabis industry in Australia has been shaping up since legalisation and what these developments could mean for investors. Read on to see what you need to know about investing in cannabis down under.


Australia cannabis investing: Market overview

As mentioned, Australia's parliament passed legislation to allow the cultivation of cannabis for medicinal and research purposes in 2016 by amending the Narcotic Drugs Act 1967. Cannabis companies have been cropping up in the country in the years since then.

While the cannabis industry is still young, Australia's agricultural sector is well established. According to the Australian Bureau of Agricultural and Resource Economics and Sciences, the nation's agriculture output is valued at AU$61 billion and is one of the largest contributors to GDP. The country's agriculture export prowess means it may be able to capitalise on the trend of moving medical marijuana products internationally.

Recreational cannabis use isn't legal in most parts of Australia. The exception is the Australian Capital Territory, which in early 2020 made it legal to possess and personally use small amounts of cannabis. That said, according to the Australian Institute of Health and Welfare (AIHW), cannabis is the most widely used illicit drug in the country. In a report, the AIHW notes that 85 percent of Australians now favour cannabis use for medical purposes, up from 69 percent in 2013.

Medical cannabis in the country is overseen by the Office of Drug Control, which issues three types of licences: research, manufacturing of a drug or product and cultivation or production of medical cannabis. As of November 2020, a total of 13 research licences, 29 cannabis cultivation or production licences and 33 manufacturing licences were held by medical cannabis companies in Australia.

Medical cannabis users do face a bit of difficulty accessing the drug. Patients can only receive medicinal cannabis products via a specialist and then may have to wait up to a month for government approval.

Some of the largest names in Canada's cannabis landscape, such as Aurora Cannabis (NYSE:ACB,TSX:ACB) and Canopy Growth (NYSE:CGC,TSX:WEED), have substantial stakes in Australian companies. In 2018, Canopy launched Spectrum Cannabis Australia, a medical cannabis company.

In early 2019, Spectrum received its first shipment of medical cannabidiol (CBD) oil and began sales. Its goal is to support patients through imports until domestic facilities are working at full capacity.

Australia cannabis investing: How to invest

Since the country's cannabis space is still in its early stages, the Australian market hasn't yet reached its peak. However, more cannabis stocks are expected to list on the Australian Securities Exchange (ASX) in the future, which means more investment opportunities.

Elixinol Global (ASX:EXL) was formed in 2018, when Colorado-based Elixinol partnered up with Hemp Food Australia to form an international brand and launch an initial public offering.

While Hemp Food Australia manufactures and distributes hemp food and skincare products, Elixinol is a retail provider on the CBD side of things, with dietary supplements and topical cannabis products. Elixinol has focused on building a solid global footprint with operations in the Americas, Europe and Asia.

In its Q3 2020 quarterly report, Elixinol said that revenues across its business units increased by 18 percent over the previous quarter, with 25 percent of the company's global sales coming from e-commerce and 65 percent of global sales associated with higher-margin products.

Another big player in the Australian space is Cann Group (ASX:CAN,OTC Pink:CNGGF). Established in 2014, Cann Group was the first cannabis company to be issued a cannabis research licence and the first to be issued a medical cannabis cultivation licence by the Australian government.

It's since worked to develop and supply cannabis, cannabis resin and medical cannabis products to patients for everything from multiple sclerosis to chronic pain.

In an agreement announced in November 2020, Cann Group secured a AU$50 million loan from National Australia Bank to fund a first stage expansion of its new Mildura growing facility in Victoria. Once completed, Cann Group will have the capacity to produce 12,500 kilograms per year of dry cannabis flower for international and domestic medical cannabis markets. This move puts Cann Group ahead in terms of production in a market that is still largely driven by imports.

There is also Althea Group (ASX:AGH), a producer, supplier and exporter of pharmaceutical-grade medicinal marijuana; it received its licence to cultivate medical cannabis in 2018. Currently, the company operates in regulated medical cannabis markets, including Australia and the UK.

In late 2020, the company received approval to sell cannabis products in Germany. The approval made Althea Germany's first commercial supplier of made-in-Australia medical cannabis products. The German medical cannabis market is expected to be worth approximately AU$2.4 billion by 2025, as per the Market Herald.

Althea has made outreach an important part of its business model, as shown by its Althea Concierge platform, a free online service that allows healthcare professionals to access treatment plans with information about specific Althea marijuana products.

Australia cannabis investing: Future outlook

In 2019, the medical cannabis industry in Australia was valued at a slight US$171.7 million, but a forecast from Prohibition Partners, a market consultancy for the cannabis sector, projects huge growth in value over the next five years. By 2024, the total legal cannabis market in Australia is expected to hit US$1.23 billion.

Australia's domestic market may be “somewhat capped by the region's population." However, Prohibition Partners points out that “overseas exports represent an opportunity for the region to significantly increase its value and establish a strong presence in the global market."

Alongside the legalisation of medical cannabis was the legalisation of overseas exports in 2018, and Australia has big plans for the growth of its international presence. “We'd like to be potentially the world's number one supplier," said Australian Health Minister Greg Hunt on a local radio station.

Because of its proximity to the region, Australia is also well positioned to break into the burgeoning Asian market, which has become more attractive since the legalisation of medical marijuana in South Korea and Thailand. In response, some companies in Australia, such as Cann Group, have already made investments towards building larger facilities to meet the demand.

There's also been talk about the legalisation of cannabis for recreational use in response to growing support for complete cannabis legalisation across the country. As noted, the Australian Capital Territory recently became the country's first state to make it legal to grow or possess cannabis for personal use.

Overall, while recreational marijuana is still illegal in Australia, the growth of the country's medical cannabis industry — and the Australian marijuana companies that exist within it — is a growing opportunity.

This is an updated version of an article first published by the Investing News Network in 2019.

Don't forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

Australia Mining Update: H1 2021 in Review

Click here to read the previous Australia mining update.

After an uncertain 2020 for the Australian mining industry, the resource market showed signs of a sharp recovery in the first six months of the new year.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

Investing in Lithium in Australia

After the country became the world’s largest lithium producer in 2018, many market participants are wondering if investing in lithium in Australia is a good option

Without a doubt, the energy revolution is here to stay, with forecasts for electric vehicle (EV) sales increasing every day. As a result, demand for lithium, a key element in the lithium-ion batteries used to power electric cars, is expected to triple by 2025 — reaching about 1 million tonnes in size.

Keep reading... Show less

How to Buy Bitcoin in Australia

Investors looking for decentralised assets (and potentially major gains) in a post-COVID-19 Australia are turning in droves to cryptocurrencies.

Bitcoin in particular is getting Aussies excited after its price hit record highs in March 2021, and again the next month. As a finite resource, its volatility is proving exciting for many market watchers.

For those interested in jumping into the space, the Investing News Network has put together a step-by-step guide on how to start buying bitcoin in Australia — and how to stay safe while doing so.

Keep reading... Show less

Nickel Stocks in Western Australia

Nickel gets a lot of love these days. Besides its applications as a base metal, it's discovering a rising popularity as an electric vehicle metal thanks to its role in battery technology.

Nickel is a vital component in lithium-ion batteries, which are seeing "hockey stick"-like production rates around the world as electric vehicles become more prevalent.

According to the Australian government, the country holds around 19.7 million tonnes in economic demonstrated reserves of the metal, making it a top nation for nickel reserves, as well as a top nation for nickel production with 180,000 tonnes produced in 2019.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

When Will Australia Legalise Recreational Cannabis?

Recreational cannabis remains illegal in all Australia’s states and territories with the exception of the Australian Capital Territory (ACT). But could that change in the future?

So far there are no clear indicators as to when or if Australia could legalise recreational cannabis, but attitudes seem to be changing. Public support is growing, and there’s even some political acceptance.

Read on to learn more about when Australia may legalise recreational cannabis.

Keep reading... Show less

A State-by-State Guide to Cannabis in Australia

Australia made waves when it federally legalised medicinal cannabis in 2016, and its marijuana market has experienced significant growth since then.

A study from FreshLeaf Analytics pegs Australian medical market sales at AU$95 million in 2020, while research firm Prohibition Partners indicates that Oceania’s cannabis industry is expected to be worth US$1.55 billion by 2024; medicinal cannabis is expected to account for 40 percent of the industry.

Despite that growth, the country’s cannabis industry is still young. Recreational use is not yet in sight, and even medical access remains limited and highly regulated.

Keep reading... Show less

Australian Cannabis: Forecasts, Analysis and Expert Advice

Are you ready to start investing in Australia’s growing cannabis market?

Dive right in with our FREE Special Report, Australian Cannabis: Forecasts, Analysis and Expert Advice

Keep reading... Show less

Cannabis in the ACT: The Market a Year Post-Legalisation

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Top News

Related News